Pathos - Series D
$365M Raised
Pathos just lit the fuse on biotech’s next big bang, and this one isn’t just about better drugs, it’s about a smarter war plan against cancer.
A company born in Chicago’s tech crucible and now marching from a Manhattan HQ, Pathos AI just closed a $365M Series D at a $1.6B valuation. And they didn’t get there by selling promises or AI snake oil. They got there by building one of the most sophisticated engines in oncology drug development, and backing it with real-world data, clinical muscle, and a vision so sharp it cuts through the noise like a scalpel.
Credit to co-founder and chairman Eric Lefkofsky, the architect behind Tempus, Groupon, and a few billion-dollar blueprints you’ve definitely clicked through. But the torch is now in the hands of CEO Iker Huerga, a data assassin who spent years fine-tuning oncology algorithms at AstraZeneca and Tempus. The man doesn’t talk AI, he codes it into clinical trials. Add in board member and original co-founder Ryan Fukushima, and you’ve got a founding trio that doesn’t bet, they calculate, synthesize, and strike.
This round? It's not just another funding headline. It's a war chest for advancing Pathos' Phase2 and Phase3 clinical programs, Pocenbrodib, a CBP/p300 inhibitor battling prostate cancer, and P-500, a PRMT5inhibitor aiming at gliomas with surgical precision. These aren’t just molecules. They’re loaded weapons, tested with models that cut patient recruitment timelines by 40% and predict responses better than today’s “standard biomarkers.”
But the real flex is the PathOS platform, a petabyte-scale AI system training on 2.5 million clinical records, 500,000 genomic profiles, and deep stacks of pathology and radiology images. It’s not chatbots and hype. It’s federated learning across 37 hospital networks, 8.4 petaflops of compute, and AI outputs landing in Nature Cancer and on-stage at ASCO.
And if you're wondering where the pharma world stands on all this? AstraZeneca just dropped a $200M collab with Pathos and Tempus to build an AI model across 12 cancers. Not to mention the Rain Oncology acquisition and licensing deals with Prelude and Novo Nordisk stacking up like clinical chess moves.
The lesson? Smart money isn’t chasing buzzwords, it’s backing biotech with backbone. Real data, real science, real execution. And in a market sprinting toward a $93B AI drug discovery future, Pathos AI isn’t following the path, they’re laying it.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
If engineering peace of mind is what you crave, Vention is your zen.